Reply to John Samuel Banerji's Letter to the Editor re: Constantijn H.J. Muselaers, Otto C. Boerman, Egbert Oosterwijk, Johannes F. Langenhuijsen, Wim J.G. Oyen, Peter F.A. Mulders. Indium-111–Labeled Girentuximab ImmunoSPECT as a Diagnostic Tool in Clear Cell Renal Cell Carcinoma. Eur Urol 2013;63:1101–6

doi:10.1016/j.eururo.2013.06.054

European Urology

Volume 64, Issue 4, October 2013, Page e83

https://doi.org/10.1016/j.eururo.2013.06.054 Get rights and content

Section snippets

Conflicts of interest

P.F.A. Mulders, W.J.G. Oyen, O.C. Boerman, and E. Oosterwijk serve or have served on an advisory board for Wilex AG. The other authors have nothing to disclose.

References (4)

C.H.J. Muselaers et al.
Indium-111–labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma
Eur Urol
(2013)
A.B. Stillebroer et al.
Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma
Eur Urol
(2013)

There are more references available in the full text version of this article.

Cited by (0)

View full text